The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity
- PMID: 309922
- PMCID: PMC2185097
- DOI: 10.1084/jem.148.6.1560
The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity
Abstract
It was shown that of four syngeneic, murine tumors investigated, only those that evoked the generation of a state of concomitant anti-tumor immunity were susceptible to endotoxin-induced regression. Moreover, the temporal relationship between the generation of concomitant immunity and the onset of susceptibility to endotoxin-induced regression points to the likely possibility that tumor regression depends on the preceding acquisition of the specifically-sensitized, effector T cells that express concomitant immunity. It is suggested that endotoxin-induced hemorrhagic necrosis which invariably precedes tumor regression serves to create conditions inside the tumor that are conducive to the entry and the functioning of effector T cells. It is also suggested that tumor necrosis factor causes hemorrhagic necrosis rather than tumor regression.
Similar articles
-
The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.J Exp Med. 1978 Dec 1;148(6):1550-9. doi: 10.1084/jem.148.6.1550. J Exp Med. 1978. PMID: 309921 Free PMC article.
-
The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma.J Exp Med. 1988 Mar 1;167(3):1086-99. doi: 10.1084/jem.167.3.1086. J Exp Med. 1988. PMID: 3258350 Free PMC article.
-
Modulation of antitumor immunity--immunobiologic approaches.Springer Semin Immunopathol. 1982;5(2):193-220. doi: 10.1007/BF00199796. Springer Semin Immunopathol. 1982. PMID: 6293113 Review. No abstract available.
-
Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour.Immunology. 1987 Mar;60(3):367-73. Immunology. 1987. PMID: 2952585 Free PMC article.
-
Studies on host defenses enhanced by endotoxins: a brief review.Klin Wochenschr. 1982 Jul 15;60(14):735-9. doi: 10.1007/BF01716566. Klin Wochenschr. 1982. PMID: 6750227 Review.
Cited by
-
A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages.Cancers (Basel). 2023 Sep 19;15(18):4635. doi: 10.3390/cancers15184635. Cancers (Basel). 2023. PMID: 37760603 Free PMC article.
-
Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells.J Exp Med. 1982 Feb 1;155(2):557-73. doi: 10.1084/jem.155.2.557. J Exp Med. 1982. PMID: 6977009 Free PMC article.
-
Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors.Am J Pathol. 1996 Feb;148(2):473-83. Am J Pathol. 1996. PMID: 8579110 Free PMC article.
-
Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6886-91. doi: 10.1073/pnas.94.13.6886. Proc Natl Acad Sci U S A. 1997. PMID: 9192661 Free PMC article.
-
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.Cancer Chemother Pharmacol. 1994;35(2):153-60. doi: 10.1007/BF00686639. Cancer Chemother Pharmacol. 1994. PMID: 7987993
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical